vs
Side-by-side financial comparison of ALBANY INTERNATIONAL CORP (AIN) and Pediatrix Medical Group, Inc. (MD). Click either name above to swap in a different company.
Pediatrix Medical Group, Inc. is the larger business by last-quarter revenue ($493.8M vs $321.2M, roughly 1.5× ALBANY INTERNATIONAL CORP). Pediatrix Medical Group, Inc. runs the higher net margin — 6.8% vs 4.3%, a 2.5% gap on every dollar of revenue. On growth, ALBANY INTERNATIONAL CORP posted the faster year-over-year revenue change (12.0% vs -1.7%). Over the past eight quarters, ALBANY INTERNATIONAL CORP's revenue compounded faster (1.2% CAGR vs -0.1%).
Albany International Corp is a global advanced materials and industrial technology company. It operates two core segments: Machine Clothing producing custom engineered fabrics for paper and other industrial manufacturing processes, and Engineered Composites developing high-performance composite components primarily for the aerospace and defense sectors, serving customers across North America, Europe, Asia and other global regions.
Pediatrix Medical Group, Inc. is a leading U.S. specialized medical service provider focusing on maternal-fetal care, neonatology, pediatric cardiology and other pediatric subspecialties. It partners with U.S. healthcare facilities to deliver evidence-based care to women, newborns and children.
AIN vs MD — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $321.2M | $493.8M |
| Net Profit | $13.9M | $33.7M |
| Gross Margin | 31.1% | — |
| Operating Margin | 9.3% | 9.9% |
| Net Margin | 4.3% | 6.8% |
| Revenue YoY | 12.0% | -1.7% |
| Net Profit YoY | -21.5% | 10.5% |
| EPS (diluted) | $0.56 | $0.40 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $321.2M | $493.8M | ||
| Q3 25 | $261.4M | $492.9M | ||
| Q2 25 | $311.4M | $468.8M | ||
| Q1 25 | $288.8M | $458.4M | ||
| Q4 24 | $286.9M | $502.4M | ||
| Q3 24 | $298.4M | $511.2M | ||
| Q2 24 | $332.0M | $504.3M | ||
| Q1 24 | $313.3M | $495.1M |
| Q4 25 | $13.9M | $33.7M | ||
| Q3 25 | $-97.8M | $71.7M | ||
| Q2 25 | $9.2M | $39.3M | ||
| Q1 25 | $17.4M | $20.7M | ||
| Q4 24 | $17.7M | $30.5M | ||
| Q3 24 | $18.0M | $19.4M | ||
| Q2 24 | $24.6M | $-153.0M | ||
| Q1 24 | $27.3M | $4.0M |
| Q4 25 | 31.1% | — | ||
| Q3 25 | -19.1% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 33.4% | — | ||
| Q4 24 | 31.5% | — | ||
| Q3 24 | 30.3% | — | ||
| Q2 24 | 33.9% | — | ||
| Q1 24 | 34.7% | — |
| Q4 25 | 9.3% | 9.9% | ||
| Q3 25 | -44.6% | 13.8% | ||
| Q2 25 | 7.2% | 12.8% | ||
| Q1 25 | 9.8% | 7.0% | ||
| Q4 24 | 8.5% | 7.8% | ||
| Q3 24 | 8.4% | 6.6% | ||
| Q2 24 | 12.9% | -31.3% | ||
| Q1 24 | 12.4% | 3.2% |
| Q4 25 | 4.3% | 6.8% | ||
| Q3 25 | -37.4% | 14.5% | ||
| Q2 25 | 2.9% | 8.4% | ||
| Q1 25 | 6.0% | 4.5% | ||
| Q4 24 | 6.2% | 6.1% | ||
| Q3 24 | 6.0% | 3.8% | ||
| Q2 24 | 7.4% | -30.3% | ||
| Q1 24 | 8.7% | 0.8% |
| Q4 25 | $0.56 | $0.40 | ||
| Q3 25 | $-3.37 | $0.84 | ||
| Q2 25 | $0.31 | $0.46 | ||
| Q1 25 | $0.56 | $0.24 | ||
| Q4 24 | $0.57 | $0.37 | ||
| Q3 24 | $0.57 | $0.23 | ||
| Q2 24 | $0.79 | $-1.84 | ||
| Q1 24 | $0.87 | $0.05 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $112.3M | $375.2M |
| Total DebtLower is stronger | $455.7M | $570.5M |
| Stockholders' EquityBook value | $726.2M | $865.9M |
| Total Assets | $1.7B | $2.2B |
| Debt / EquityLower = less leverage | 0.63× | 0.66× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $112.3M | $375.2M | ||
| Q3 25 | $108.3M | $340.1M | ||
| Q2 25 | $106.7M | $224.7M | ||
| Q1 25 | $119.4M | $99.0M | ||
| Q4 24 | $115.3M | $229.9M | ||
| Q3 24 | $127.2M | $103.8M | ||
| Q2 24 | $116.4M | $19.4M | ||
| Q1 24 | $125.4M | $8.0M |
| Q4 25 | $455.7M | $570.5M | ||
| Q3 25 | $480.6M | $577.2M | ||
| Q2 25 | $444.7M | $583.9M | ||
| Q1 25 | $416.4M | $590.5M | ||
| Q4 24 | $318.5M | $597.1M | ||
| Q3 24 | $362.2M | — | ||
| Q2 24 | $377.1M | — | ||
| Q1 24 | $439.1M | — |
| Q4 25 | $726.2M | $865.9M | ||
| Q3 25 | $739.3M | $890.7M | ||
| Q2 25 | $888.6M | $833.8M | ||
| Q1 25 | $900.0M | $789.2M | ||
| Q4 24 | $943.5M | $764.9M | ||
| Q3 24 | $991.0M | $732.5M | ||
| Q2 24 | $967.5M | $706.5M | ||
| Q1 24 | $967.5M | $856.2M |
| Q4 25 | $1.7B | $2.2B | ||
| Q3 25 | $1.7B | $2.2B | ||
| Q2 25 | $1.7B | $2.1B | ||
| Q1 25 | $1.7B | $2.0B | ||
| Q4 24 | $1.6B | $2.2B | ||
| Q3 24 | $1.8B | $2.1B | ||
| Q2 24 | $1.8B | $2.0B | ||
| Q1 24 | $1.8B | $2.2B |
| Q4 25 | 0.63× | 0.66× | ||
| Q3 25 | 0.65× | 0.65× | ||
| Q2 25 | 0.50× | 0.70× | ||
| Q1 25 | 0.46× | 0.75× | ||
| Q4 24 | 0.34× | 0.78× | ||
| Q3 24 | 0.37× | — | ||
| Q2 24 | 0.39× | — | ||
| Q1 24 | 0.45× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $73.7M | $114.1M |
| Free Cash FlowOCF − Capex | $51.4M | — |
| FCF MarginFCF / Revenue | 16.0% | — |
| Capex IntensityCapex / Revenue | 6.9% | — |
| Cash ConversionOCF / Net Profit | 5.31× | 3.39× |
| TTM Free Cash FlowTrailing 4 quarters | $82.6M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $73.7M | $114.1M | ||
| Q3 25 | $43.9M | $137.3M | ||
| Q2 25 | $32.7M | $137.2M | ||
| Q1 25 | $2.1M | $-117.5M | ||
| Q4 24 | $78.5M | $133.0M | ||
| Q3 24 | $47.0M | $91.8M | ||
| Q2 24 | $83.4M | $107.0M | ||
| Q1 24 | $9.6M | $-125.2M |
| Q4 25 | $51.4M | — | ||
| Q3 25 | $25.9M | — | ||
| Q2 25 | $18.8M | — | ||
| Q1 25 | $-13.5M | — | ||
| Q4 24 | $60.2M | — | ||
| Q3 24 | $31.6M | — | ||
| Q2 24 | $63.6M | — | ||
| Q1 24 | $-17.3M | — |
| Q4 25 | 16.0% | — | ||
| Q3 25 | 9.9% | — | ||
| Q2 25 | 6.0% | — | ||
| Q1 25 | -4.7% | — | ||
| Q4 24 | 21.0% | — | ||
| Q3 24 | 10.6% | — | ||
| Q2 24 | 19.2% | — | ||
| Q1 24 | -5.5% | — |
| Q4 25 | 6.9% | — | ||
| Q3 25 | 6.9% | — | ||
| Q2 25 | 4.5% | — | ||
| Q1 25 | 5.4% | — | ||
| Q4 24 | 6.4% | — | ||
| Q3 24 | 5.2% | — | ||
| Q2 24 | 6.0% | — | ||
| Q1 24 | 8.6% | — |
| Q4 25 | 5.31× | 3.39× | ||
| Q3 25 | — | 1.91× | ||
| Q2 25 | 3.56× | 3.49× | ||
| Q1 25 | 0.12× | -5.66× | ||
| Q4 24 | 4.44× | 4.36× | ||
| Q3 24 | 2.61× | 4.72× | ||
| Q2 24 | 3.39× | — | ||
| Q1 24 | 0.35× | -31.03× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AIN
| Transferred At Point In Time | $176.5M | 55% |
| Engineered Composites Other | $99.3M | 31% |
| Engineered Composites ASC | $44.5M | 14% |
| Transferred Over Time | $1.0M | 0% |
MD
| Health Care Patient Service | $421.6M | 85% |
| Hospitals Contracts | $70.0M | 14% |
| Other | $2.2M | 0% |
